Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABSK 043

Next Previous
Drug Profile

ABSK 043

Alternative Names: ABSK-043

Latest Information Update: 26 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbisko Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Liver cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 08 Dec 2025 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer released by Abbisko Therapeutics
  • 03 Nov 2025 Abbisko Therapeutics initiates a phase II trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in China (PO) (NCT07164170)
  • 10 Sep 2025 Abbisko Therapeutics plans a phase II trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in China (PO) in September 2025 (NCT07164170)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top